Fibrinogen Concentrate (Human)(Fibrinogen Concentrate (Human)) - 药物靶点：Fibrinogen_在研适应症：出血_专利_临床

概要

基本信息

药物类型

血液提取物

别名

Haemocomplettan、Riastap

靶点

Fibrinogen

作用方式

刺激剂

作用机制

纤维蛋白原刺激剂

治疗领域

其他疾病

在研适应症

出血

非在研适应症

获得性纤维蛋白原缺乏纤维蛋白原缺乏血症主动脉瘤+ [4]

原研机构

ProMetic Biotherapeutics Ltd.

在研机构

CSL Behring GmbH

非在研机构

CSL Behring LLC

最高研发阶段批准上市

首次获批日期

美国 (2009-01-16),

出血

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

47

项与 Fibrinogen Concentrate (Human) 相关的临床试验

NCT06582420

/ Not yet recruitingN/AIIT

Pre-hospital Administration of Fibrinogen Concentrate in Patients With Suspected Trauma-Induced Coagulopathy (PAF-TIC)

A prospective, randomized controlled trial of fibrinogen concentrate (FC) plus standard of care versus standard of care alone in adult trauma patients with major bleeding or presumed major bleeding is developed to evaluate the efficacy and safety of prehospital administration of FC in trauma patients with suspected hypofibrinogenemia and active bleeding or presumed to be bleeding.
The main endpoints are:
1. Plasma fibrinogen levels in the first blood sample drawn at the patient's arrival at the trauma room and/or similar emergency bay dedicated to trauma and reanimation above the critical threshold of 2.0 g/l. As fibrinogen decreases early in trauma, its deficiency predicts massive bleeding and death.
2. Administration feasibility of FC within the prehospital setting.
Patients will be randomly assigned to receive either standard trauma care or standard trauma care plus administration of FC.

开始日期2025-01-01

申办/合作机构-

CTRI/2024/09/073878

/ Not yet recruiting临床3期IIT

Evaluation of the effect of fibrinogen on peripartum hemorrhage in Placenta accreta spectrum (PAS) disorders, a double blind randomized controlled trial. - NIL

开始日期2024-09-24

申办/合作机构-

EUCTR2022-001759-17-DE

/ Not yet recruiting临床3期

A multicenter, randomized, double-blind, placebo-controlled, parallel, phase 3 study to assess the efficacy and safety of fibrinogen concentrate (FGTW) in the management of bleeding in patients undergoing complex cardiac surgery (involving CPB)

开始日期2023-03-15

申办/合作机构

Laboratoire Français du Fractionnement et des Biotechnologies

100 项与 Fibrinogen Concentrate (Human) 相关的临床结果

登录后查看更多信息

100 项与 Fibrinogen Concentrate (Human) 相关的转化医学

登录后查看更多信息

100 项与 Fibrinogen Concentrate (Human) 相关的专利（医药）

登录后查看更多信息

552

项与 Fibrinogen Concentrate (Human) 相关的文献（医药）

2025-04-01·ANESTHESIA AND ANALGESIA

A Randomized Controlled Trial Comparing Effectiveness of Different Fibrinogen Preparations in Restoring Clot Firmness

Article

作者: Ranucci, Marco ; Aloisio, Tommaso ; Caravella, Giuseppe ; Baryshnikova, Ekaterina ; Di Dedda, Umberto ; Anguissola, Martina ; Barbaria, Alessandro

BACKGROUND::

Different preparations of fibrinogen concentrate are currently available. Two in vitro studies demonstrated the superiority of FibCLOT (LFB) in increasing clot firmness with respect to RiaSTAP (CSL Behring). The present trial involved a clinical model to test the hypothesis of superiority, with the increase in clot firmness as the primary end point.

METHODS::

Forty cardiac surgery patients were randomly allocated to receive a dose of 30 mg/kg FibCLOT or RiaSTAP after protamine administration in the presence of microvascular bleeding and a FIBTEM maximum clot firmness (MCF) <10 mm. Viscoelastic parameters were measured before and after fibrinogen supplementation: FIBTEM MCF, EXTEM MCF, and EXTEM clotting time (CT).

RESULTS::

The mean increase in FIBTEM MCF was 4 ± 1.2 mm (mean and standard deviation) in the FibCLOT group and 4 ± 1.6 mm in the RiaSTAP group (P = 1.000); the mean decrease in CT was 11. 2 ± 12.2 (mean and standard deviation) seconds in the FibCLOT group and 14. 8 ± 13 seconds in the RiaSTAP group (P = .372). In both groups, fibrinogen supplementation induced a significant (P = .001) increase in the FIBTEM MCF and EXTEM CT. The proportions of patients who did not experience an increase of 4 mm in the RiaSTAP group and the FibCLOT group were not statistically significantly higher (35% vs 20%, respectively, relative risk 2.15, 95% confidence interval 0.52–9.00, P = .288).

CONCLUSIONS::

In contrast to previous in vitro studies, we found that the effect of FibCLOT on MCF and CT was not significantly greater than that of RiaSTAP in cardiac surgery patients. Further studies in other clinical settings are warranted.

2025-03-01·SEMINARS IN THROMBOSIS AND HEMOSTASIS

The History of Rare Bleeding Disorders

Review

作者: Hassani, Saeed ; Feily, Zahra ; Yassini, Mahya S. ; Torkamandi, Mohammad S. ; Ramezanzadeh, Narjes ; Fathalizade, Kimia ; Mahalleh, Roghayeh Gholizadeh Doran ; Hashemi, Farzaneh ; Dorgalaleh, Akbar ; Kohzadi, Zhino ; Khademi, Melika ; Tavasoli, Behnaz

Abstract:

Deficiencies in coagulation factors I (FI), FII, FV, combined FV and FVIII (CF5F8) and vitamin K-dependent coagulation factors FVII, FX, FXI, and FXIII have been referred to as rare bleeding disorders (RBDs), rare coagulation factor deficiencies (RCFDs), or recessively inherited coagulation disorders. Fibrinogen was most likely the first member of this group to be identified, with reports of its discovery spanning from 1859 to 1966. If not, then the first coagulation factor to be identified was prothrombin in 1894, and the last coagulation factor to be found was FX in 1956, about 60 years later. The first patient to be diagnosed with an RBD was a 9-year-old boy with afibrinogenemia in 1920 and the vitamin K-dependent coagulation factors deficiency was the most recent RBD in this group to be identified in a 3-month-old child in 1966. The initial therapeutic option for nearly all patients with RBDs was whole blood transfusion; this was replaced in 1941 by fresh frozen plasma (FFP), and then in later years by cryoprecipitate and coagulation factor concentrates. Fibrinogen concentrate was the first coagulation factor concentrate produced in 1956. Coagulation factor concentrate is now available for FI, FVII, FX, FXI, and FXIII; however, FFP and/or platelet transfusion are the only treatments available for FV deficiency. The only recombinant concentrates available for RBDs are for FVII and FXIII, which date from 1988 and the 2000s, respectively. Even though the clinical presentations, diagnosis, and management of lesser-known bleeding disorders have improved significantly in recent decades, more studies are needed to reveal the hidden aspects of these disorders in order to overcome diagnostic and therapeutic challenges and ultimately improve the quality of life for those who are affected.

2025-03-01·PEST MANAGEMENT SCIENCE

Synthesis of antibiofilm (1R,4S)‐(−)‐fenchone derivatives to control Pseudomonas syringae pv. tomato

Article

作者: Li, Linjing ; Feng, Juntao ; Wang, Yong ; Wang, Delong ; Zhou, Jianbo ; Fang, Yali ; Li, Yunpeng ; Chen, Yizhe ; Zhang, Zhijia ; Min, Shuoling

Abstract:

BACKGROUND:

Biofilm plays a crucial role in Pseudomonas syringae pv. tomato (Pst) infection. We identified (1R,4S)‐(−)‐fenchone (FCH) as the most potent antibiofilm agent against Pst among 39 essential oil compounds. Subsequently, we synthesized a series of FCH oxime ester and acylhydrazine derivatives to explore more potent derivatives.

RESULTS:

II3 was screened out as the most potent derivative, exhibiting a minimal biofilm inhibitory concentration of 60 μg mL−1 and a lowest concentration with maximal biofilm inhibition (LCMBI) of 200 μg mL−1, lower than those of FCH (80 and 500 μg mL−1, respectively). II3 and FCH showed minimum inhibitory concentration values >1000 μg mL−1 and similar maximal biofilm inhibition extents of 48.7% and 49.5% at their respective LCMBIs, respectively. Meanwhile, neither of them influenced cell viability or the activity of metabolic enzymes at their respective LCMBIs. II3 at its LCMBI significantly reduced biofilm thickness, extracellular polysaccharide content, and pectinase and cellulase production indices. In vivo assay results indicated that II3 could preventatively reduce the bacterial contents in tomato leaves at its LCMBI, and when combined with kasugamycin (KSG) (10 μg mL−1), II3 achieved the same level of bacterial reduction as the sole application of KSG (70 μg mL−1), thereby reducing the required dosage of KSG. Mechanistic studies demonstrated that II3 can down‐regulate biofilm‐related genes and inhibit PsyR/PsyI quorum sensing system, which differs from the bactericidal mechanisms.

CONCLUSION:

These results underscore the potential of II3 as an antibiofilm agent for the control of Pst or FCH as a promising natural candidate for future in‐depth optimization. © 2024 Society of Chemical Industry.

2

项与 Fibrinogen Concentrate (Human) 相关的新闻（医药）

2024-02-14

·FiercePharma

Grifols readies US, EU approval push for blood clot treatment after phase 3 success

BT524 can be administered to “patients on the operating table immediately," Grifols explained. Grifols is readying an approval run at U.S. and European regulators on the back of a phase 3 win for the Spanish plasma medicine producer's concentrated form of a blood clotting factor. The product, dubbed BT524, is a concentrated form of fibrinogen, a glycoprotein that is essential for blood clot formation and stops excessive bleeding resulting from injuries or surgery. Grifols was testing BT524 in a late-stage study of patients with acquired fibrinogen deficiency (AFD), which it described as an “underserved growth market.” The Barcelona, Spain-based company announced this morning that the product had met the study’s primary endpoint, demonstrating its noninferiority to standard of care when it came to reducing blood loss in patients with AFD who underwent spinal or abdominal surgery, while also “maintaining an excellent safety profile.” Specifically, mean blood loss was 1,444 mL among the BT524 cohort compared with 1,735 mL among patients who received standard of care. It meant patients receiving Grifols’ product lost an average of 291 mL less blood. AFD usually occurs during surgery when a patient’s body contains insufficient fibrinogen to arrest bleeding. It is typically treated with a plasma extract called cryoprecipitate or fresh frozen plasma, which both contain fibrinogen. However, both of these treatment options contain various other unneeded proteins and elements, meaning that large volumes are required to ensure the patient receives sufficient fibrinogen, Grifols explained in the release. They also need to be thawed before use, which is not only time-consuming but can put patients’ lives at risk, the company added. In contrast, BT524 can be administered to “patients on the operating table immediately,” who will only receive the fibrinogen necessary to prevent hemorrhaging, Grifols explained. The company’s plan is to kick off the approval process in both Europe and the U.S. in the fourth quarter of the year. If successful, it would mark the first fibrinogen concentrate approved for AFD in the U.S., Grifols noted. “The positive results for fibrinogen are an important milestone and strengthen a Grifols innovation strategy that’s diversified across plasma and non-plasma, balanced between internal and external investments, and includes both shorter- and longer-term development cycles,” Grifols’ chief operating officer, Victor Grifols Deu, said in the release. While Grifols has its eye on the first fibrinogen concentrate approval for AFD in the U.S., its competitors have had more luck getting their own versions to market for congenital fibrinogen deficiency. CSL Behring got RiaSTAP approved in that indication as far back as 2009, while Switzerland’s Octapharma followed suit with Fibryga in 2017. Since then, Fibryga has also received approval to treat AFD across Europe off the back of a phase 2 study. Meanwhile, Grifols is in the midst of an ongoing legal battle with Gotham City Research after the New York hedge fund accused the company of wrongful accounting practices.

上市批准临床结果临床3期临床2期

2021-06-11

·BioSpace

Fibrinogen Concentrate Market Size to Reach USD 4.19 Billion in 2028, Says Reports and Data

Increasing preference for fibrinogen concentrate over fresh-frozen plasma, rising incidence of bleeding disorders, and increasing number of fibrinogen product approvals are some key factors driving market growth Market Size – USD 2.61 Billion in 2020, Market Growth – at a CAGR of 6.1%, Market Trends – Rising R&D investment to accelerate development of advanced fibrinogen products The global fibrinogen concentrate market size is expected to reach USD 4.19 Billion in 2028 at a CAGR of 6.1%, according to the latest report by Reports and Data. Increasing R&D activities to develop new therapies for bleeding disorders, rising demand for fibrinogen concentrates to treat congenital deficiencies, and high incidence of bleeding disorders across the globe are key factors expected to drive market revenue growth over the forecast period. In addition, increasing number of advanced and innovative in pipeline to treat bleeding disorders is also expected to contribute to revenue growth of the market going ahead. Fibrinogen concentrate is a lyophilized and purified human plasma fibrinogen and is widely used as an alternative to traditional sources of fibrinogen, which is a natural blood protein playing a vital role in coagulation process. Fibrinogen concentrate has been extensively used and recommended for bleeding disorders and acquired coagulation disorders in several countries across the globe as it significantly improves blood clot firmness and minimizes the need for postoperative transfusion. Fibrinogen concentrate can either be plasma-derived or a recombinant and is often used for afibrinogenemia and dysfibrinogenemia. Increasing research is being carried out across the globe to expand its application scope to use it for conditions such as hemorrhage resuscitation. This is expected to contribute to revenue growth of the market going ahead. New product launches and approvals of fibrinogen concentrates are also expected to be a key factor driving market growth. In addition, increasing focus of key players on developing advanced fibrinogen concentrates to treat bleeding disorders is also a key market growth driving factor. However, adverse reactions associated with fibrinogen concentrate such as arterial thrombosis, dyspnea, nausea, and others are expected to hamper market growth to a certain extent over the forecast period. Access Free sample PDF Copy of the Report @ Some Key Highlights from the Report: Human fibrinogen type segment is expected to account for largest revenue share in the global market over the forecast period owing to increasing need for fibrinogen concentrate to treat bleeding disorders and congenital coagulation deficiencies. Congenital fibrinogen deficiency segment is expected to register robust revenue CAGR over the forecast period owing to high incidence of hemophilia, rising rate of bleeding disorders, proven safety and efficiency of fibrinogen concentrates and rapid advancements in fibrinogen products. North America is expected to dominate other regional markets over the forecast period owing to increasing geriatric population and high rate of bleeding disorders, advancements in diagnostics and therapeutics, and robust presence of key players in the region. Major companies in the market include CSL Behring, Baxter, Johnson & Johnson (Ethicon), LFB Group, ProFibrix BV (The Medicines Company), Shanghai RAAS, Jiangxi Boya Bio-Pharmaceutical, Hualan Biological Engineering, Harbin Pacific Biopharmaceutical, and Greencross. In November 2019, Octapharma AG announced approval for use of fibryga, which is a lyophilised human fibrinogen concentrate for intravenous infusion, in treatment of acquired fibrinogen deficiency in 15 European countries. Buy now your Exclusive copy of Report @ For the purpose of this report, Reports and Data has segmented the global fibrinogen concentrate market on the basis of type, application type, and region: Type Outlook (Revenue, USD Billion; Volume in Tons, 2018–2028) Human Animal Application Type Outlook (Revenue, USD Billion; Volume in Tons, 2018–2028) Congenital Fibrinogen Deficiency Surgical Procedures Request for Custom Research @ Regional Outlook (Revenue, USD Billion; Volume in Tons, 2018–2028) North America U.S. Canada Mexico Europe Germany U.K. France Italy BENELUX Rest of APAC Asia Pacific China India Japan South Korea Rest of APAC Latin America Brazil Rest of Latin America Middle East & Africa U.A.E. Saudi Arabia South Africa Rest of MEA Explore Reports and Data's Prime Analysis of the global Pharmaceutical & Healthcare Industry: Hemostasis Analyzers Market Analysis, By Product (Laboratory analyzer, POC testing,) By Test Type (Prothrombin Time, Fibrinogen, Activated Partial and others) By Technology Type (Mechanical and others) By End-Use (Diagnostic Centers, Hospitals, and others), Forecasts to 2026 Product (Revenue, USD Million; 2016-2026) Bovine Blood Plasma Derivatives Market Size, Share & Trends, By Type (Bovine Serum, FBS, Bovine Serum Albumin, Fibrinogen, Protein Ingredient, Others), By Application (Scientific Research, Industrial Production, Feed, Others), And Regional Forecasts To 2027 Coagulation Analyzers Market Size, Share & Analysis, By Product, By Technology (Mechanical, Electrochemical) By Test Types (APTT, D-Dimer, Fibrinogen, PT) By End Use (Hospitals, Research Institutes), And Segment, Forecasts To 2028 About Reports and Data Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Contact Us: John W Head of Business Development Reports and Data | Web: Direct Line: +1-212-710-1370 E-mail: sales@reportsanddata.com Read Full Press Release:

100 项与 Fibrinogen Concentrate (Human) 相关的药物交易

登录后查看更多信息

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
出血	美国	CSL Behring GmbH	2009-01-16

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
获得性纤维蛋白原缺乏	临床3期	-	CSL Behring LLC	2009-10-01
纤维蛋白原缺乏血症	临床3期	-	CSL Behring LLC	2009-10-01
产后出血	临床2期	-	CSL Behring LLC	2021-01-01
冠心病	临床2期	美国	CSL Behring LLC	2011-01-01
心脏瓣膜疾病	临床2期	美国	CSL Behring LLC	2011-01-01
心脏病	临床2期	巴西	CSL Behring LLC	2010-08-01
主动脉瘤	临床2期	德国	CSL Behring LLC	2008-06-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03932240 (Pubmed \| Anesth Analg)	临床3期	一线	36	Cryoprecipitate	蓋觸廠夢網遞築繭壓鹹(蓋窪製淵艱蓋艱膚製顧) = 淵觸願壓製廠齋壓觸觸網獵鏇獵顧願鏇艱選鬱 (顧壓夢願廠窪網廠獵艱, -1081.3 ~ -10.4) 更多	积极	2024-08-08
				Fibrinogen concentrate (RiaSTAP)	蓋觸廠夢網遞築繭壓鹹(蓋窪製淵艱蓋艱膚製顧) = 餘憲鏇鑰膚鏇網淵遞鹹網獵鏇獵顧願鏇艱選鬱 (顧壓夢願廠窪網廠獵艱, 291.1 ~ 1361.9) 更多
NCT03932240 (CTgov)	临床3期	-	36	Fibrinogen Concentrate (FC) (Fibrinogen Concentrate (FC))	選構選製範遞製膚製鬱(夢顧衊膚鏇遞鑰壓襯襯) = 衊網繭製淵製蓋餘網窪蓋鏇鏇艱醖遞鬱壓鏇糧 (獵廠鏇獵構憲鑰願壓繭, 夢鏇繭網築鑰觸遞襯窪 ~ 齋膚簾構襯遞簾淵鹹顧) 更多	-	2023-03-20
				Cryoprecipitate (Cryoprecipitate)	選構選製範遞製膚製鬱(夢顧衊膚鏇遞鑰壓襯襯) = 鹽網鏇範糧艱製憲窪鑰蓋鏇鏇艱醖遞鬱壓鏇糧 (獵廠鏇獵構憲鑰願壓繭, 艱醖積鹹鏇構憲繭窪鑰 ~ 壓鑰窪餘鏇壓齋淵餘構) 更多
NCT02822599 (RiaSTAP, CTgov)	临床4期	出血 \| 纤维蛋白原缺乏血症	30	RiaStAP (RiaSTAP)	蓋窪鹽淵壓積觸願鬱鏇(齋鑰鹹繭繭齋淵憲憲壓) = 鬱鏇鏇願築網構鏇鑰廠憲壓遞鬱觸糧選獵鑰夢 (淵顧繭遞觸衊窪夢構夢, 蓋鬱齋願願夢齋襯衊艱 ~ 願鏇鏇衊築艱衊鹽夢製) 更多	-	2021-09-16
				Saline (Saline)	蓋窪鹽淵壓積觸願鬱鏇(齋鑰鹹繭繭齋淵憲憲壓) = 鹹糧襯繭遞積憲醖憲繭憲壓遞鬱觸糧選獵鑰夢 (淵顧繭遞觸衊窪夢構夢, 製構鹽築範襯糧簾顧鏇 ~ 鹹糧獵製窪觸窪窪淵繭) 更多
ISTH2020	N/A	血小板减少症	-	Fibrinogen concentrate	醖糧衊夢網窪齋夢遞製(襯範願蓋襯醖衊蓋齋遞) = 齋遞構衊獵鹽醖鹹膚鹹繭憲遞網選齋積網鹽鬱 (壓遞繭艱膚築鏇襯壓膚 )	-	2020-07-12
NCT01623531 (CTgov)	临床3期	术中并发症	62	Fibrinogen (RiaSTAP)	膚積鹹鏇範糧廠鹹網衊(窪憲鏇衊獵鑰顧繭壓簾) = 壓網襯廠鑰構網獵顧製範糧構膚壓艱齋衊淵鬱 (鹽鹽獵鏇壓襯衊鏇鑰襯, 範齋網衊衊築鬱糧衊顧 ~ 蓋鏇構網餘網餘蓋襯築) 更多	-	2020-05-22
				Fibrinogen (Intravenous Saline)	膚積鹹鏇範糧廠鹹網衊(窪憲鏇衊獵鑰顧繭壓簾) = 襯鹹廠積構齋醖鹽積壓範糧構膚壓艱齋衊淵鬱 (鹽鹽獵鏇壓襯衊鏇鑰襯, 顧醖艱選願願獵壓夢範 ~ 網夢餘築廠願夢鹽膚願) 更多
ESC2018	N/A	-	299	Fibrinogen concentrate	製製網淵蓋憲廠襯衊鹽(膚艱遞艱構艱築糧鹹築) = 顧鏇夢鏇構衊齋築築膚積選鑰選糧鏇觸製襯鬱 (觸製衊齋鏇鹹蓋築鹹鏇 ) 更多	积极	2018-08-27
				Fibrinogen concentrate	製製網淵蓋憲廠襯衊鹽(膚艱遞艱構艱築糧鹹築) = 構鏇鏇製膚繭壓積廠艱積選鑰選糧鏇觸製襯鬱 (觸製衊齋鏇鹹蓋築鹹鏇 ) 更多
NCT02540434 (TOP-CLOT, CTgov)	N/A	凝血障碍	19	RiaSTAP+ROTEM (RiaSTAP Arm)	鏇範膚襯艱鹽範襯齋遞(構膚鏇憲糧鑰艱糧鏇糧) = 鑰壓願鏇繭簾積簾選窪糧製鏇願齋膚觸簾膚醖 (鹹膚艱顧觸艱夢衊淵壓, 鑰窪構簾艱鏇築艱範襯 ~ 醖觸顧範積鏇構範蓋鏇) 更多	-	2017-05-12
				Cryoprecipitate (Cryopreciptiate Arm)	鏇範膚襯艱鹽範襯齋遞(構膚鏇憲糧鑰艱糧鏇糧) = 蓋壓夢蓋積憲鏇鹹壓遞糧製鏇願齋膚觸簾膚醖 (鹹膚艱顧觸艱夢衊淵壓, 憲蓋淵簾壓餘艱蓋觸膚 ~ 網艱餘簾餘觸鬱願鹽膚) 更多
NCT01283321 (RiaCT, CTgov)	临床2期	冠心病 \| 心脏瓣膜疾病	26	Human fibrinogen concentrate (Group A: RiaSTAP)	繭窪襯餘願艱衊齋願鏇(齋選壓獵衊廠鏇鹹鏇衊) = 憲願範醖網顧齋鑰獵艱齋膚遞壓鏇齋繭網鬱壓 (鏇顧壓衊網構築願觸窪, 0.0) 更多	-	2015-02-16
				apheresis platelets (Group B: Apheresis Platelets)	繭窪襯餘願艱衊齋願鏇(齋選壓獵衊廠鏇鹹鏇衊) = 築鑰鑰淵醖範鹹製夢蓋齋膚遞壓鏇齋繭網鬱壓 (鏇顧壓衊網構築願觸窪, 0.3) 更多
NCT03884725 (Pubmed \| J Thorac Cardiovasc Surg)	临床4期	-	63	Fibrinogen concentrate	選製顧鹽艱壓壓膚壓網(糧築願鏇觸獵醖簾憲夢) = 獵蓋顧憲糧壓窪願壓醖繭鏇蓋鹽淵鹽積壓淵鏇 (壓齋淵簾獵積醖膚繭鹽, 157 ~ 750)	积极	2014-10-01
				Cryoprecipitate	選製顧鹽艱壓壓膚壓網(糧築願鏇觸獵醖簾憲夢) = 遞衊願淵糧夢簾製醖齋繭鏇蓋鹽淵鹽積壓淵鏇 (壓齋淵簾獵積醖膚繭鹽, 215 ~ 510)
NCT01300286 (CTgov)	临床4期	出血	23	RiaSTAP	餘製襯願網獵艱糧顧觸(艱齋觸蓋廠鏇壓網鹽鹹) = 齋醖憲廠選膚繭鬱繭鏇觸鹽壓壓製簾衊衊獵鹽 (衊壓淵齋築膚鏇願艱選, 49) 更多	-	2014-06-16